Resource summary impact report
NICE has recommended tenecteplase as an option for the thrombolytic treatment of an acute ischaemic stroke in adults:
- within 4.5 hours of the onset of stroke symptoms, and
- when intracranial haemorrhage has been excluded.
Use the least expensive option of the available treatments (including tenecteplase and alteplase). Take account of administration costs, dosages, price per dose and commercial arrangements. If the least expensive option is unsuitable, people with the condition, their family or carers, and their healthcare professional should discuss the advantages and disadvantages of other treatments.
We expect the resource impact of implementing the recommendations in England will be less than £5 million per year (or approximately £8,800 per 100,000 population, based on a population for England of 57.1 million people).
This is because the technology is a further treatment option and the overall cost of treatment will be similar for this patient group.
This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.
The payment mechanism for the technology is determined by the responsible commissioner and depends on the technology being classified as high cost.
This page was last updated: